The 9 most recent market catalysts affecting $BEAT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 28, 2026
Corporate Catalyst
Neutral
Impact 55
HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026
HeartBeam has announced it will present the results of its ALIGN-ACS clinical study at the TCT 2026 conference. This filing is a forward-looking announcement about an event schedul…
Oct 26, 2026
Corporate Catalyst
Bullish
Impact 85
HeartBeam Receives FDA Clearance for Acute Myocardial Infarction Assessment Technology
HeartBeam, Inc. has received FDA clearance for its technology designed to assess acute myocardial infarction. This is a crucial regulatory milestone for the company, as it validate…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 60
HeartBeam Completes Enrollment for HEADSTART-ACS Study
HeartBeam, Inc. has successfully completed patient enrollment for its HEADSTART-ACS study, a clinical trial aimed at the early detection of heart attacks. This achievement is signi…
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 65
HeartBeam Completes Enrollment Ahead Of Schedule In 486-Patient HEADSTART-ACS Study
HeartBeam (BEAT) announced the early completion of enrollment for its 486-patient HEADSTART-ACS study, evaluating its 3D ECG system for heart attack detection. This is a positive d…
Oct 5, 2026
Corporate Catalyst
Bullish
Impact 95
HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System
HeartBeam, Inc. announced that its at-home cardiac assessment tool received Breakthrough Device Designation from the FDA. This designation is highly significant as it grants the co…
Oct 5, 2026
Corporate Catalyst
Bullish
Impact 85
HeartBeam shares are trading higher after the company announced it received the FDA Breakthrough Device Designation for the HeartBeam System as a tool for assessing potential heart attacks at home.
The FDA Breakthrough Device Designation is a major positive for HeartBeam as it signifies the agency's recognition of the device's potential to provide more effective treatment or …
Oct 5, 2026
Corporate Catalyst
Bullish
Impact 75
HeartBeam Receives FDA Breakthrough Device Designation For Its HeartBeam System For Assessing Potential Heart Attacks At Home
HeartBeam announced that its 3D ECG technology for assessing potential heart attacks at home has received FDA Breakthrough Device Designation. This is a significant corporate catal…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 65
HeartBeam Wins U.S. Patent Expanding ECG Device With Acoustic Sensing, Impedance Features For Heart Disease Monitoring
HeartBeam announced the allowance of a new U.S. patent that significantly expands the capabilities of its ECG device to include acoustic sensing and thoracic impedance measurement.…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.